Growth suppression and apoptosis induction in synovial sarcoma cell lines by a novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ)

Keisuke Horiuchi, Hideo Morioka, Kazumasa Nishimoto, Yoshihisa Suzuki, Michiro Susa, Robert Nakayama, Akira Kawai, Hiroshi Sonobe, Hironari Takaishi, Toshifumi Ozaki, Hiroo Yabe, Kazuo Umezawa, Yoshiaki Toyama

研究成果: Article査読

11 被引用数 (Scopus)

抄録

Synovial sarcoma is a relatively common soft tissue sarcoma with an aggressive clinical course. Although surgery is currently the first treatment modality, improvement of adjuvant chemotherapy is deemed essential to improve the clinical outcome. Nuclear factor-κB (NF-κB) is constitutively activated in various cancer cells and has emerged as a potential therapeutic molecular target; however, the possible involvement of NF-κB in the pathology of sarcomas remains to be clarified. Herein we examined the effects of a novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ) on two synovial sarcoma-derived cell lines, HS-SY-II and SYO-1. The growth of both cell lines was completely inhibited by DHMEQ and apoptosis was induced at 10 μg/ml. Additionally, we found that DHMEQ showed additive effects when used in combination with other cytotoxic agents. These observations indicate that inhibition of NF-κB activity may serve as a potential therapeutic target for synovial sarcoma.

本文言語English
ページ(範囲)336-344
ページ数9
ジャーナルCancer Letters
272
2
DOI
出版ステータスPublished - 2008 12月 18

ASJC Scopus subject areas

  • 腫瘍学
  • 癌研究

フィンガープリント

「Growth suppression and apoptosis induction in synovial sarcoma cell lines by a novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ)」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル